Business Update

Clinicians expect Bristol-Myers Squibb's Baraclude use to increase for treatment of hepatitis B

Published in Hepatitis Weekly, August 28th, 2006

Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that after one year on the market, more than 25% of clinicians surveyed say that they prescribe Bristol-Myers Squibb's Baraclude as a first-line therapy for the treatment of hepatitis B and that clinicians expect that Baraclude usage will increase in the next two to three years.

The new PhysicianForum report entitled Hepatitis B: New Antivirals Replacing the Old', also finds that while clinician use of Baraclude will increase, Baraclude and Gilead's Hepsera are facing hurdles in achieving favorable tier status amongst surveyed private health...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2006-08-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry